| |
|
|
|
Xtalks, Online
2025-05-07
The landscape of cell and gene therapies (CGTs) is undergoing a significant transformation, expanding beyond oncology into the treatment of autoimmune diseases.
This shift is driven by the success of chimeric antigen receptor (CAR)-T therapies in hematologic malignancies, the growing unmet need in autoimmune disorders and advancements in immunomodulatory techniques such as regulatory T cells (Tregs) and gene editing technologies like CRISPR. Additionally, regulatory agencies and biopharmaceutical companies are increasingly investing in this field, recognizing its potential for widespread clinical impact.
With over 80 recognized autoimmune diseases affecting millions globally, existing treatments rely on symptom management rather than curative approaches. The application of CGTs offers a promising new frontier for restoring immune tolerance and achieving long-term remission; however, the unique challenges such as disease complexity, immune system risks, scalability and cost considerations must be carefully navigated.
The successful implementation of CGTs for autoimmune diseases requires an approach that integrates expertise in immunology, genetic and cellular engineering, and regulatory compliance for living therapies. Patient-physician engagement and education are also critical for adoption and accessibility.
This webinar will explore the key drivers behind the transition from oncology to autoimmune and the essential considerations needed to advance CGTs in autoimmune disease treatment. Through case studies and industry insights, this webinar will provide a comprehensive overview of the shift in clinical research priorities and the future of CGTs in autoimmune disease treatment.
Register for this webinar to explore the exciting evolution in regenerative medicine and immunotherapy.
Keywords: Rare Disease, Drug Development, Clinical Research, Cell Therapy, Rare Disease Clinical Trials, CAR T-Cell Therapy, Cell and Gene Therapy, Cell & Gene Therapies, Rare Diseases/Orphan Drugs
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Desmond Cabrera, Vice President, Global Head, Cell and Gene Therapy, Allucent
Dr. Brian Abbott, MD, Executive Medical Director, Therapeutic Area Medical Lead, Oncology/Hematology, Allucent
Stephanie Stempf, Project Director, Global Project Leadership, Clinical Project Management, Allucent
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-05-07
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|